Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 63
Filter
1.
Eur J Clin Microbiol Infect Dis ; 35(8): 1315-21, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27197725

ABSTRACT

The main purpose of this study was to assess the actual occurrence of Gram-negative oxidase-positive bacteria (GNOP) in human wounds caused by animals, mostly cat and dog bites and scratches, and with signs of infection. We report a prospective series of 92 wound samples. Routine culturing was combined with a procedure optimised for fastidious GNOP. All GNOP isolates were identified by 16S rDNA sequencing to the species level. We observed a more prominent role of GNOP, including at least 30 species mostly in the families Flavobacteriaceae, Neisseriaceae and Pasteurellaceae, and less of Staphylococcus aureus and streptococci. The antibiotic susceptibility pattern was investigated, as GNOP are associated with sudden onset of serious infections, making an early decision on antibiotic treatment vital. All GNOP isolates judged to be clinically relevant displayed susceptibility to ampicillin and meropenem, but resistance to oxacillin, clindamycin and gentamicin was frequent. Our findings emphasise the need to cover GNOP as recommended in guidelines, and not only common wound pathogens, when treating an animal-caused wound.


Subject(s)
Ampicillin/pharmacology , Anti-Bacterial Agents/pharmacology , Bites and Stings/microbiology , Cats , Dogs , Gram-Negative Bacteria/drug effects , Animals , DNA, Bacterial/analysis , DNA, Bacterial/genetics , Gram-Negative Bacteria/isolation & purification , Humans , Microbial Sensitivity Tests
2.
Eur J Clin Microbiol Infect Dis ; 33(3): 313-24, 2014 Mar.
Article in English | MEDLINE | ID: mdl-23990136

ABSTRACT

Immune activation is a regular feature of sepsis, but the incidence and nature of the ensuing inflammation-resolving and immunosuppressive component is less well understood. In this study, we compared immunoregulatory markers on blood leukocytes from patients with Gram-negative or Gram-positive sepsis or septic shock, and compared this to blood from patients with severe virosis or healthy controls. To this end, blood from 32 patients with sepsis, including ten cases with shock, and 12 patients with severe virosis were analysed by flow cytometry for the expression levels of monocyte HLA-DR, CD11c, CD14 and CD40, and for frequencies of CD163(+)-suppressive monocytes, HLA-DR(+) or CD40(+)-activated T cells and Tregs. Plasma cytokine levels were analysed as a functional measurement. Signs of immunosuppression dominated in the septic shock and Gram-positive sepsis groups, whereas monocyte activation was common in Gram-negative sepsis patients without shock. However, the main finding was the large inter-individual variation of immune activation and immunosuppression, with no correlation to prognosis among the shock patients. The pronounced inter-individual variation in the analysed monocyte and lymphocyte markers forms a strong argument that, when immunomodulatory treatment is considered in a sepsis patient, it should be personalised and guided by a detailed immune status assessment.


Subject(s)
Bacteremia/immunology , Shock, Septic/immunology , Adult , Aged , Aged, 80 and over , Antigens, CD , Antigens, Differentiation, Myelomonocytic , Bacteremia/blood , Bacteremia/microbiology , Biomarkers/blood , Cytokines/blood , Female , Humans , Immunophenotyping , Male , Middle Aged , Monocytes/immunology , Receptors, Cell Surface , Shock, Septic/blood , T-Lymphocytes/immunology , Young Adult
3.
Scand J Immunol ; 78(2): 194-204, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23679576

ABSTRACT

Wnt5a is a non-canonical Wnt protein that is expressed at elevated levels in inflammatory conditions. Its role in inflammation remains unclear, although it is known that Wnt5a is expressed at a higher level in monocyte-derived myeloid dendritic cells (Mo-mDCs) than in monocytes and macrophages. The function of Wnt5a in dendritic cells (DCs) remains relatively unexplored. Here, we found that under Mo-mDC culture conditions, Wnt5a inhibited the generation of CD14(⁺/low) Mo-mDCs while promoting the generation of CD14⁺/⁺⁺ CD16⁺ monocytes. We could further show that stimulation of monocytes with rWnt5a induced a rapid IL-6 production and that the rWnt5a treated Mo-mDC differentiation was restored upon blocking of IL-6. Also, conditioned media from Wnt5a stimulated human breast cancer cells producing IL-6, specifically inhibited Mo-mDC differentiation. These observations are strengthened by our finding that patients with sepsis, a disease involving elevated Wnt5a and IL-6 levels, also showed a significant increase in the CD14⁺ CD16⁺⁺/CD14⁺/⁺⁺ CD16⁺ monocyte populations, which was accompanied by a significant decrease in circulating mDCs. We finally show that under typical Mo-mDC culture conditions, monocytes isolated from patients with sepsis as compared to healthy controls, preferentially differentiated into CD14CD14⁺/⁺⁺ HLA-DR⁺⁺ cells. We suggest that Wnt5a is a possible candidate mediator for the CD14⁺/⁺⁺ CD16⁺ monocyte accumulation seen in patients with infectious disease and cancer.


Subject(s)
Dendritic Cells/drug effects , Macrophages/drug effects , Monocytes/drug effects , Proto-Oncogene Proteins/genetics , Sepsis/pathology , Wnt Proteins/genetics , Case-Control Studies , Cell Differentiation/drug effects , Cell Line, Tumor , Culture Media, Conditioned/pharmacology , Dendritic Cells/immunology , Dendritic Cells/pathology , Gene Expression Regulation , HLA-DR Antigens/genetics , HLA-DR Antigens/immunology , Humans , Immunophenotyping , Interleukin-6/antagonists & inhibitors , Interleukin-6/biosynthesis , Interleukin-6/immunology , Lipopolysaccharide Receptors/genetics , Lipopolysaccharide Receptors/immunology , Macrophages/immunology , Macrophages/pathology , Monocytes/immunology , Monocytes/pathology , Primary Cell Culture , Proto-Oncogene Proteins/immunology , Proto-Oncogene Proteins/pharmacology , Receptors, IgG/genetics , Receptors, IgG/immunology , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/pharmacology , Sepsis/genetics , Sepsis/immunology , Signal Transduction , Wnt Proteins/immunology , Wnt Proteins/pharmacology , Wnt-5a Protein
4.
Eur Respir J ; 39(1): 59-66, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21719486

ABSTRACT

Particles in exhaled air (PEx) may reflect the composition of respiratory tract lining fluid (RTLF); thus, there is a need to assess their potential as sources of biomarkers for respiratory diseases. In the present study, we compared PEx from patients with asthma and controls using time-of-flight-secondary ion mass spectrometry (TOF-SIMS) and multivariate analysis. Particles were collected using an instrument developed in-house. 15 nonsmoking subjects with physician-diagnosed asthma and 11 nonsmoking healthy controls performed 10 consecutive forced exhalations into the instrument. Particle concentrations were recorded and samples of particles collected on silicon plates were analysed by TOF-SIMS. Subjects with asthma exhaled significantly lower numbers of particles than controls (p=0.03) and the ratio of unsaturated to saturated phospholipids was significantly lower in samples from subjects with asthma (0.25 versus 0.35; p=0.036). Orthogonal partial least squares-discriminant analysis models showed good separation between both positive and negative spectra. Molecular ions from phosphatidylcholine and phosphatidylglycerol, and protein fragments were found to discriminate the groups. We conclude that analysis of PEx is a promising method to examine the composition of RTLF. In the present explorative study, we could discriminate between subjects with asthma and healthy controls based on TOF-SIMS spectra from PEx.


Subject(s)
Asthma/physiopathology , Exhalation , Respiration , Spectrometry, Mass, Secondary Ion/methods , Adult , Biomarkers , Case-Control Studies , Female , Humans , Least-Squares Analysis , Male , Middle Aged , Multivariate Analysis , Phospholipids/chemistry , Principal Component Analysis , Surface-Active Agents
5.
Br J Pharmacol ; 155(7): 1085-92, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18806816

ABSTRACT

BACKGROUND AND PURPOSE: Experimental and clinical investigations have revealed that statins can downregulate both acute and chronic inflammatory processes. Whether statins express anti-inflammatory activities in the treatment of Crohn's disease is unknown. EXPERIMENTAL APPROACH: Ten patients were given 80 mg atorvastatin once daily for 13 weeks and then followed up for 8 weeks after the treatment. The anti-inflammatory effects of statin were assessed by measuring levels of plasma C-reactive protein (CRP), soluble (s) CD14, tumour necrosis factor (TNF)-alpha, sTNFRI and II, CCL2 and 8 and the mucosal inflammation by faecal calprotectin. Circulating monocytes were subgrouped and their chemokine receptor expression of CCR2 and CX(3)CR1 were analysed. KEY RESULTS: In 8 of 10 patients, atorvastatin treatment reduced CRP (P=0.008) and sTNFRII (P=0.064). A slight decrease in plasma levels of sCD14, TNF-alpha and sTNFRI was observed in 7/10 patients and faecal calprotectin was reduced in 8/10 patients. We also observed that the treatment diminished expression of CCR2 and CX(3)CR1 on monocyte populations (P=0.014). At the follow-up visit, 8 weeks after the atorvastatin treatment was terminated, CRP levels had returned to those seen before the treatment. CONCLUSIONS AND IMPLICATIONS: Our findings imply that atorvastatin therapy reduces inflammation in patients with Crohn's disease and, therefore, encourage further investigations of statin-mediated protective effects in inflammatory bowel diseases.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Crohn Disease/drug therapy , Heptanoic Acids/pharmacology , Pyrroles/pharmacology , Adult , Atorvastatin , C-Reactive Protein/drug effects , C-Reactive Protein/metabolism , CX3C Chemokine Receptor 1 , Chemokine CCL2/drug effects , Chemokine CCL2/metabolism , Chemokine CCL8/drug effects , Chemokine CCL8/metabolism , Crohn Disease/physiopathology , Female , Follow-Up Studies , Gene Expression Regulation/drug effects , Humans , Leukocyte L1 Antigen Complex/drug effects , Leukocyte L1 Antigen Complex/metabolism , Lipopolysaccharide Receptors/blood , Lipopolysaccharide Receptors/drug effects , Male , Monocytes/drug effects , Monocytes/metabolism , Receptors, CCR2/drug effects , Receptors, CCR2/metabolism , Receptors, Chemokine/drug effects , Receptors, Chemokine/metabolism , Receptors, Tumor Necrosis Factor, Type I/drug effects , Receptors, Tumor Necrosis Factor, Type I/metabolism , Receptors, Tumor Necrosis Factor, Type II/drug effects , Receptors, Tumor Necrosis Factor, Type II/metabolism , Tumor Necrosis Factor-alpha/drug effects , Tumor Necrosis Factor-alpha/metabolism , Young Adult
6.
Scand J Rheumatol ; 35(1): 1-6, 2006.
Article in English | MEDLINE | ID: mdl-16467033

ABSTRACT

The purpose of this review is to give a modern view and an update of important areas in primary Sjögren's syndrome (SS), which may be the most common of the autoimmune systemic rheumatic diseases. Interest in aspects of primary SS including clinical manifestations, pathogenesis, aetiology, treatment, prognosis, etc has increased during the past three decades, the volume of scientific papers and the number of theses being the indicators. However, only a fraction of the money that is used for research into rheumatoid arthritis (RA) is used for SS, and the statement that SS is under-diagnosed, under-treated and under-researched will still be valid for several years to come. The topics that are focused on in this review are: (a) clinical areas with subsections on signs and symptoms, terminology, predictors for development of non-Hodgkin malignant lymphoma (NHML) and prognosis, (b) treatment, (c) the Danger model (aetiopathogenesis) and (d) pathology, including immunoglobulin G4 (IgG4)-positive cells.


Subject(s)
Sjogren's Syndrome/drug therapy , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Murine-Derived , Bromhexine/therapeutic use , Expectorants/therapeutic use , Humans , Immunologic Factors/therapeutic use , Models, Biological , Rituximab , Sjogren's Syndrome/immunology , Sjogren's Syndrome/physiopathology
8.
Scand J Immunol ; 61(1): 98-107, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15644129

ABSTRACT

Serial sections of lower lip salivary gland (LSG) biopsies were examined by immunohistochemistry, using a battery of B- and partly T-related antibodies (CD5, CD20, CD21, CD27, CD38, CD45RO, CD79a, Bcl-2 and Bcl-6) in different groups of subjects: healthy controls and clinically verified smoking or nonsmoking cases of primary Sjögren's syndrome (SS). The purpose was to characterize the B-cell pattern of the lymphocytic foci and of the tiny perivascular infiltrates preceding the development of foci. Hyperplastic tonsil was used as stain control. In normal LSG, widely dispersed CD38+ and CD79a+ as well as some CD5+ cells are a normal constituent, with lack of staining with the other antibodies. In SS/LSG, the lymphocytic foci showed staining with all the antibodies, with variable degrees of overlapping or nonoverlapping. In SS/LSG of nonsmokers, CD20+ B cells make up a prominent part of the fully developed periductal lymphocytic foci, not overlapping with CD45RO. Also, CD20+ B cells did not overlap in the infiltrates with colocalized CD27+/CD38+ cells. CD20+ B cells and CD45RO+ T cells also occur as minute infiltrates perivascularly in areas of no foci in SS/LSG as well as in SS smokers lacking the typical foci. Smokers lack foci, but tiny infiltrates express CD20 as well CD45R0. Our findings suggest that CD20+ B cells and CD45RO+ T cells are early immigrants in the LSG of SS of smokers as well as nonsmokers and that another subgroup of CD27+/CD38+ B cells gradually mix with the first two to form the characteristic foci in SS/LSG. The simultaneous demonstration of CD20+ and CD27+ B cells in SS/LSG may constitute a significant diagnostic tool. Further, the findings suggest that the early immigrating lymphocytes may have been primed at a site remote from the glands before arriving via the blood to the gland tissue.


Subject(s)
B-Lymphocyte Subsets/immunology , Sjogren's Syndrome/immunology , ADP-ribosyl Cyclase/metabolism , ADP-ribosyl Cyclase 1 , Antigens, CD/metabolism , Antigens, CD20/metabolism , B-Lymphocyte Subsets/pathology , Case-Control Studies , Humans , Immunohistochemistry , Lip , Membrane Glycoproteins , Salivary Glands/immunology , Salivary Glands/pathology , Sjogren's Syndrome/pathology , Tumor Necrosis Factor Receptor Superfamily, Member 7/metabolism
9.
Rheumatology (Oxford) ; 43(9): 1109-15, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15213331

ABSTRACT

OBJECTIVE: To examine the stress response, including the role of DNA-dependent protein kinase (DNA-PK), in B cells from Sjögren's syndrome (SS) patients. METHODS: B-cell lines were exposed to gamma radiation and then postincubated to allow inducible stress functions to develop. The magnitude of the DNA damage response was monitored with respect to DNA-PK phosphorylation of a p53 peptide, defence protein levels (Ku, DNA-PK catalytic subunit, ATM, p21 and p53) and flow cytometric determination of cell cycle phases and apoptosis. RESULTS: B cells from SS patients, compared with healthy controls, displayed enhancement of two stress functions in undamaged cells: DNA-PK kinase activity and apoptosis. In addition, SS showed enhanced cell cycle arrest in gamma-irradiated cells. CONCLUSIONS: Strong kinase activity of DNA-PK, functioning not only in a DNA damage response but also in immunoglobulin gene rearrangement, may be an important component of the heightened stress response displayed by SS cells. In combination with recent reports, our data indicate that constitutional hyper-reactivity to danger signals is a basic pathogenetic factor in SS.


Subject(s)
B-Lymphocytes/physiology , Protein Serine-Threonine Kinases/metabolism , Sjogren's Syndrome/physiopathology , Antigens, Nuclear/metabolism , Apoptosis/physiology , Ataxia Telangiectasia Mutated Proteins , B-Lymphocytes/enzymology , Cell Cycle/physiology , Cell Cycle Proteins , Cell Line , DNA Damage/physiology , DNA-Activated Protein Kinase , DNA-Binding Proteins/analysis , DNA-Binding Proteins/metabolism , Flow Cytometry/methods , HeLa Cells , Humans , Ku Autoantigen , Nuclear Proteins/metabolism , Phosphorylation , Protein Serine-Threonine Kinases/analysis , Sjogren's Syndrome/enzymology , Stress, Physiological/physiopathology , Transcription Factors/analysis , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins
11.
Acta Paediatr ; 91(6): 636-40, 2002.
Article in English | MEDLINE | ID: mdl-12162593

ABSTRACT

UNLABELLED: The aim of this study was to monitor the Helicobacter pylori antibody seroprevalence of an asymptomatic cohort between the ages of 4 and 18 y. The H. pylori antibody titres in a longitudinally followed cohort of 168 native Swedish children (born between 1972 and 1974) were established at 4, 8, 12, 16, and 18 y of age. Seventeen children (10.1%) were found positive on at least one occasion when a paediatric cut-off was applied. Five children (3.0%) reached levels considered positive in adults. The seroprevalence at 4 y of age was 4.0%, at 8 y 2.5%, at 12 y 4.9%, at 16 y 5.3%, and at 18 y 6.3%. The difference in serological titres between the age groups was not significant. A change from negative to positive after the age of 4 took place in 5 of the cases. Spontaneous seroreversion appeared in 5 cases. CONCLUSION: Our findings showed no significant differences among the various age groups. Seventeen of the 168 children (10.1%) had been infected at some time, the prevalence ranging from 2.5% to 6.3%. Seroconversion and seroreversion occurred infrequently between the ages of 4 and 18 y.


Subject(s)
Antibodies, Bacterial/analysis , Helicobacter Infections/epidemiology , Helicobacter Infections/immunology , Helicobacter pylori/immunology , Adolescent , Age Distribution , Child , Child, Preschool , Cohort Studies , Female , Humans , Longitudinal Studies , Male , Prevalence , Probability , Sex Distribution , Sweden/epidemiology
12.
Eur J Clin Invest ; 32(6): 458-65, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12059992

ABSTRACT

BACKGROUND: Cells from primary Sjögren's syndrome (SS) patients have been reported to show alterations in DNA repair and p53 expression. The DNA-dependent protein kinase (DNA-PK) autoantigen may be involved in both of these alterations in relation to cellular DNA damage responses. We conducted this study of cell-cycle kinetics and p53 to find additional evidence for an abnormal stress response role in the pathogenesis of SS. DESIGN: DNA-dependent protein kinase activity, p53 peptide phosphorylation and p53 protein levels were determined in gamma-irradiated long-term T lymphocyte cultures. Cell-cycle progression of peripheral blood mononuclear cells was analysed with flow cytometry. RESULTS: No significant differences in the DNA-PK activities or p53 protein levels appeared between the SS patients and the healthy individuals. However, patients with the SS hallmark Ro/SS-A and La/SS-B autoantibodies showed enhancement of both p53 peptide phosphorylation (P = 0.036) and G1 cell-cycle arrest (P = 0.015) in response to gamma radiation. CONCLUSIONS: Sjögren's syndrome cells express an enhanced G1 checkpoint function which may be mediated partly by p53 phosphorylation, suggesting that an abnormal stress response in SS is of relevance for the development of this autoimmune disease.


Subject(s)
Cell Cycle/physiology , DNA Damage , DNA-Binding Proteins , Sjogren's Syndrome/physiopathology , Tumor Suppressor Protein p53/metabolism , Adult , Aged , Autoantibodies/immunology , Cells, Cultured , DNA Repair , DNA-Activated Protein Kinase , Female , Gamma Rays , Humans , Male , Middle Aged , Nuclear Proteins , Peptides/metabolism , Phosphorylation , Protein Serine-Threonine Kinases/metabolism , Sjogren's Syndrome/genetics , Sjogren's Syndrome/immunology , T-Lymphocytes/cytology , T-Lymphocytes/metabolism , T-Lymphocytes/radiation effects
13.
Scand J Immunol ; 54(3): 328-34, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11555398

ABSTRACT

UNLABELLED: The aim was to examine tissue expression of Ku protein in lower lip salivary gland (LSG) biopsies from cases of primary Sjögren's syndrome (SS) and from normal subjects. METHODS: immunohistochemistry was used with antibodies to Ku70/86 and also Ki67, PCNA and p53. In addition, the Klenow method was applied in order to detect evidence of apoptosis. Sections of hyperplastic tonsil served as additional controls. RESULTS: in normal controls, LSG acinar cells stained negatively whereas LSG excretory duct cell nuclei stained positively with Ku and Klenow and occasionally with PCNA but negatively with Ki67 and p53. In LSG focal sialadenitis of SS cases, some lymphocytic cells showed staining with Ku, Ki67, PCNA, Klenow and p53. In addition to duct cell Ku and Klenow as well as PCNA staining which was not much different from normals, a few ductal epithelial and also mononuclear cells stained with p53. In focal sialadenitis, some acinar cells showed staining with PCNA as well as with Klenow. CONCLUSIONS: our findings in LSG biopsies of SS cases added little to an increased understanding about the pathogenetic mechanisms in the development of focal sialadenitis in SS. However, in normal LSG, ductal epithelial but not acinar cells seem to express a constitutively specific Ku protein and Klenow profile, suggestive of DNA strand breaks but not clearly associated with ongoing apoptotic events. It may reflect an enhanced stress response, which may be pathogenetically important in the early events of focal sialadenitis development in primary Sjögren's syndrome.


Subject(s)
Antigens, Nuclear , DNA Damage , DNA Helicases , DNA-Binding Proteins/metabolism , Lip/anatomy & histology , Nuclear Proteins/metabolism , Salivary Glands/metabolism , Sjogren's Syndrome/genetics , Sjogren's Syndrome/metabolism , Antibody Specificity , Apoptosis , Cell Line , DNA Polymerase I/chemistry , DNA-Binding Proteins/immunology , DNA-Binding Proteins/physiology , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Ku Autoantigen , Nuclear Proteins/immunology , Nuclear Proteins/physiology , Palatine Tonsil/chemistry , Palatine Tonsil/metabolism , Proliferating Cell Nuclear Antigen/analysis , Salivary Glands/chemistry , Sialadenitis/genetics , Sialadenitis/metabolism , Tumor Suppressor Protein p53/analysis
14.
Biochim Biophys Acta ; 1538(2-3): 305-12, 2001 Apr 23.
Article in English | MEDLINE | ID: mdl-11336801

ABSTRACT

DNA-dependent protein kinase (DNA-PK) has been shown to take part in cell cycle regulatory signal transduction and in the repair of X-ray-induced DNA double-strand breaks. Functional DNA-PK is furthermore needed for the generation of antigen specificity during lymphocyte maturation. The Ku86 subunit of DNA-PK has been reported to exist in human B lymphocytes in a truncated form capable of binding to broken DNA but lacking the ability to activate the kinase function of DNA-PK. In the present work the Ku70 and Ku86 dimer proteins in T and B lymphocytes from human blood donors were analysed by immunoblotting and were observed apparently to be of full length. Also, nuclear protein extracted from B and non-B lymphocytes displayed DNA-dependent kinase activity. However, a minor fraction of Ku86 in lymphocytes was observed to be truncated with a molecular mass of approx. 70 kDa.


Subject(s)
Antigens, Nuclear , B-Lymphocytes/metabolism , DNA Helicases , DNA-Binding Proteins/analysis , Nuclear Proteins/analysis , T-Lymphocytes/metabolism , Cell Line , DNA-Activated Protein Kinase , DNA-Binding Proteins/chemistry , HeLa Cells , Humans , Ku Autoantigen , Molecular Weight , Monocytes/metabolism , Nuclear Proteins/chemistry , Protein Serine-Threonine Kinases/metabolism
15.
Pediatrics ; 107(1): 42-5, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11134432

ABSTRACT

OBJECTIVE: The study was designed to investigate the prevalence of celiac disease (CD) among 2.5-year-old children in a Swedish urban population with a high incidence of CD. MATERIAL AND METHODS: Six hundred ninety apparently healthy children, born in the 12-month period of July 1992 through June 1993, were screened for immunoglobulin A (IgA) antigliadin antibodies and IgA antiendomysium antibodies, and those antibody-positive at repeated testing were further investigated with intestinal biopsy. RESULTS: Of the 690 children, 6 were both IgA antigliadin antibody- and IgA antiendomysium antibody-positive, and 7 were antiendomysium antibody-positive but antigliadin antibody-negative. Jejunal biopsy, performed in 12 cases, manifested partial or total villous atrophy in 8 cases. Thus, together with an additional child whose parents declined the offered biopsy, but whose response to a gluten-free diet confirmed the presence of CD, the prevalence of CD in the study series was 1.3% (9/690; 95% confidence interval:.4-2.2). However, independent of the study, an additional 22 cases of symptomatic, biopsy-verified CD have already been detected in the birth cohort of 3004 children. CONCLUSIONS: The prevalence of CD in our study series was high, at least 1.0%, but may be as high as 2.0% if the frequency of silent CD is as high as we have found in the remaining unscreened cohort. These findings confirm that CD is one of the most common chronic disorders.


Subject(s)
Celiac Disease/diagnosis , Celiac Disease/epidemiology , Mass Screening/statistics & numerical data , Atrophy , Biopsy , Celiac Disease/diet therapy , Child, Preschool , Female , Follow-Up Studies , Humans , Immunoglobulin A/analysis , Immunoglobulin G/analysis , Jejunum/pathology , Male , Mass Screening/methods , Prevalence , Reference Values , Serologic Tests , Sweden/epidemiology
16.
Rheumatology (Oxford) ; 39(2): 142-7, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10725063

ABSTRACT

OBJECTIVE: The purpose of this study was to examine whether antibodies against CD4 are present in patients with primary Sjögren's syndrome, and to explore the possible correlation between these antibodies and the CD4+ T lymphocyte depletion that is seen in some Sjögren patients. METHODS: Sera from 214 patients with primary Sjögren's syndrome, 154 healthy blood donors, 38 age- and sex-matched controls without autoimmune disease, and 77 HIV-1-seropositive individuals were analysed by an enzyme-linked immunosorbent assay (ELISA) using recombinant soluble CD4 as the antigen. RESULTS: Anti-CD4 antibodies were observed more frequently in patients with Sjögren's syndrome (12.6%) as compared with the control groups (0.6%) (P < 0.001), and at a level similar to that seen among the HIV-1 patients (13.0%). However, no correlation was found between the presence of anti-CD4 antibodies and CD4+ T lymphocytopenia in the Sjögren patients. CONCLUSION: This is the first study that shows anti-CD4 antibodies in patients with primary Sjögren's syndrome. The significance of these antibodies in the immunopathogenesis of Sjögren's syndrome remains to be determined.


Subject(s)
CD4 Antigens/immunology , CD4-Positive T-Lymphocytes/immunology , Sjogren's Syndrome/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Antinuclear/analysis , Autoimmune Diseases/blood , Autoimmune Diseases/immunology , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , HIV Seropositivity/blood , HIV Seropositivity/immunology , Humans , Immunoglobulins/analysis , Lymphopenia , Male , Middle Aged , Recombinant Proteins , Rheumatoid Factor/analysis , Sjogren's Syndrome/blood
17.
Acta Paediatr ; 88(9): 933-6, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10519331

ABSTRACT

This study was undertaken to investigate the prevalence of coeliac disease in children and adolescents with Turner syndrome. Eighty-seven children and adolescents with Turner syndrome were screened for IgA-antiendomysium antibodies (EMA) and IgA-antigliadin antibodies (AGA), 5% (4/87) being found to be EMA-positive, and 15% (13/87) to have AGA levels above normal. Of the 10 patients who were either AGA- or EMA-positive and further investigated with intestinal biopsy, four manifested villous atrophy (i.e. all three of the EMA-positive patients, but only one of the seven AGA-positive patients). The results suggest EMA-positivity to be a good immunological marker for use in screening for coeliac disease, and such screening to be justified in patients with Turner syndrome.


Subject(s)
Antibodies, Anti-Idiotypic/blood , Celiac Disease/complications , Celiac Disease/epidemiology , Immunoglobulin A , Turner Syndrome/complications , Adolescent , Case-Control Studies , Celiac Disease/blood , Child , Enzyme-Linked Immunosorbent Assay , Female , Gliadin/immunology , Humans , Prevalence , Sweden/epidemiology
18.
Pediatrics ; 103(6 Pt 1): 1248-52, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10353937

ABSTRACT

OBJECTIVE: This study was conducted to investigate the prevalence of celiac disease (CD) in children and adolescents at diagnosis of insulin-dependent diabetes mellitus (IDDM) before insulin treatment was started. MATERIAL AND METHODS: At diagnosis of IDDM, and before treatment was started, 115 children and adolescents were screened for IgA- antiendomysium (EMA) and IgA-antigliadin antibodies (AGA). Those found to be EMA-positive and/or AGA-positive were investigated further with intestinal biopsy. RESULTS: Of the 115 patients, 2 had known CD at diagnosis of IDDM; of the remainder of patients, 6% (7/113) were found to be EMA-positive and 9% (10/113) were found to have AGA levels above normal. Of the 6 patients who underwent biopsy, 5 manifested villous atrophy. In addition, 2 patients with high EMA and AGA antibody titers refused biopsy, and 4 patients with low EMA and/or AGA titers were found to have normal titers at control before biopsy decision. CONCLUSION: Because the prevalence of CD at diagnosis of IDDM would seem to be 6% to 8%, screening for CD seems to be justified among patients with newly diagnosed IDDM.


Subject(s)
Autoantibodies/immunology , Diabetes Mellitus, Type 1/diagnosis , Gliadin/immunology , Immunoglobulin A/immunology , Muscle Fibers, Skeletal/immunology , Adolescent , Celiac Disease/immunology , Child , Diabetes Mellitus, Type 1/epidemiology , Female , Follow-Up Studies , Gliadin/blood , Humans , Immunoglobulin A/blood , Infant , Male , Prevalence , Retrospective Studies , Seroepidemiologic Studies , Sweden/epidemiology
19.
J Intern Med ; 245(5): 483-8, 1999 May.
Article in English | MEDLINE | ID: mdl-10363749

ABSTRACT

OBJECTIVES: To evaluate the influence of pretreatment IgG against streptokinase on the outcome of streptokinase treatment in acute myocardial infarction. SETTING: Coronary care unit. DESIGN: From 88 patients admitted to the coronary care unit due to chest pain, blood samples were taken for determination of the pre-existing titre of antibodies against streptokinase. The patients were treated and monitored according to standard protocols. Fifty of the patients received thrombolytic therapy with streptokinase due to acute myocardial infarction and were monitored with continuous dynamic vectorcardiography, making possible the continuous analysis of ST- and QRS-vector changes and determination of the event of reperfusion. None of these 50 patients had been given streptokinase therapy previously. RESULTS: According to the vectorcardiographic criteria 21(42%) patients had signs of early (within 2 h) reperfusion after streptokinase therapy. These patients had lower pre-existing antibody titres than patients without signs of reperfusion (mean values 0.20 and 0.45 arbitrary units, P = 0.01). None of the patients with a titre higher than 0.50 arbitrary units (nine patients) had signs of early reperfusion. Of the 41 patients with a titre lower than 0.50 arbitrary units 52.5% had signs of early reperfusion. CONCLUSION: The present investigation indicates that pre-existing streptokinase antibodies play an important role in reperfusion failure during thrombolytic therapy with streptokinase in acute myocardial infarction. Therefore, the determination of streptokinase antibodies may differentiate between those patients who may benefit from streptokinase treatment and those who should be treated with some other regime.


Subject(s)
Fibrinolytic Agents/immunology , Immunoglobulin G/metabolism , Myocardial Infarction/drug therapy , Myocardial Infarction/immunology , Streptokinase/immunology , Thrombolytic Therapy , Enzyme-Linked Immunosorbent Assay , Female , Fibrinolytic Agents/therapeutic use , Humans , Male , Middle Aged , Plasminogen Activators/immunology , Plasminogen Activators/therapeutic use , Streptokinase/therapeutic use , Vectorcardiography
20.
Mol Carcinog ; 24(3): 226-31, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10204807

ABSTRACT

Sjögren's syndrome (SS) is a systemic autoimmune disorder with a strong tumor predisposition (a 44-fold elevated incidence of non-Hodgkin's lymphoma has been reported). By polymerase chain reaction analysis of t(14;18), a key lymphomagenic event in peripheral blood lymphocytes, we found a lower frequency in a subset of 12 SS patients positive for SS-A/SS-B autoantibodies than in 21 healthy subjects and 20 SS patients lacking these SS marker autoantibodies (P < 0.001). All 14 mutants sequenced displayed signs typical of V(D)J recombinase activity. This perplexing result of a low rate of t(14;18) in a population strongly predisposed to t(14;18)-associated tumor development may be explained by a constitutive deficiency in V(D)J recombinase leading to autoimmunity and increased lymphoproliferation.


Subject(s)
Autoimmune Diseases/genetics , B-Lymphocytes/pathology , Chromosomes, Human, Pair 14/ultrastructure , Chromosomes, Human, Pair 18/ultrastructure , Lymphoma, Non-Hodgkin/genetics , Sjogren's Syndrome/genetics , Translocation, Genetic , Antibodies, Antinuclear/analysis , Autoimmunity/genetics , B-Lymphocytes/enzymology , Base Sequence , Chromosomes, Human, Pair 14/genetics , Chromosomes, Human, Pair 18/genetics , DNA Nucleotidyltransferases/deficiency , Genes, Immunoglobulin , Genes, bcl-2 , Genetic Predisposition to Disease , Humans , Immunoglobulin Heavy Chains/genetics , Molecular Sequence Data , Polymerase Chain Reaction , VDJ Recombinases
SELECTION OF CITATIONS
SEARCH DETAIL
...